Skip to content Skip to footer
Subscribe Now

INSIGHTS+

J.P. Morgan Special: Deal Maker of the Year 2023 (Part 01)
J.P. Morgan Special: Deal Maker of the Year 2023 (Part 01)
Shots: As the year began, PharmaShots was busy analyzing the deals throughout 2023 to prepare a special report, viz. JP Morgan 2024 Special: Deal Maker of the Year 2023 (Part 01) The report features Roche, that signed 26 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases Propelled by the invaluable…
January 4, 2024
Insight+_Saurabh Chaubey
Most Viewed Articles of 2023
2023, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year.   Top 20 Radiopharma Companies Based on Market Cap  Shots:  Integrating scintigraphy with…
January 2, 2024
Insights+: EMA Marketing Authorization of New Drugs in November 2023
Insights+: EMA Marketing Authorization of New Drugs in November 2023
Shots: The EMA approved 3 BLA while 6 New Chemical Entities with 1 recommendation and 1 acceptance in November 2023, leading to treatments for patients and advances in the healthcare industry In November 2023, the major highlighted drugs were Vyjuvek to Treat Dystrophic Epidermolysis Bullosa (DEB) and Vyvgart with Halozyme’s Enhanze for the treatment of…
December 29, 2023
Top Performing Drug – Xtandi (December Edition)
Top Performing Drug – Xtandi (December Edition)
Shots:   In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Xtandi and prepared a curated analysis report for our readers  Xtandi is indicated for the treatment of certain prostate cancers  PharmaShots presents a concise take on the key features of Xtandi with…
December 28, 2023
New Drug Designations - November 2023
New Drug Designations – November 2023
Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, EMA and China. This month’s report includes 3 biological drugs, 12 small molecules, 13 cell and gene therapies, 1 peptide, 3 exosome-based therapy and 4 devices  Atsena Therapeutics’ capsid AAV.SPR gene therapy, focused on the treatment of Leber congenital…
December 27, 2023
Know Your Investor: Google Ventures
Know Your Investor: Google Ventures
Shots:  An investment arm of Alphabet Inc., Google Ventures Management Company colossally in seed stage companies, in diverse fields ranging from software and internet to healthcare, life sciences, and artificial intelligence among others  Since 2016, GV has shifted its focus from seed-stage companies to evolved companies. With over $8B worth of assets under the management…
December 27, 2023
Insights+: The US FDA New Drug Approvals in November 2023
Insights+: The US FDA New Drug Approvals in November 2023 
Shots:  The US FDA approved 5 NDAs & 4 BLAs in November 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 109 novel products in 2023  In November 2023, the major highlights drugs were Wezlana (ustekinumab) approved for Multiple Inflammatory Diseases, and Cosentyx (secukinumab) for the Treatment…
December 20, 2023
Disease of the Month - Pancreatic Cancer
Disease of the Month – Pancreatic Cancer
Shots To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research   Continuing the series for the Disease of the Month, PharmaShots brings a condensed report on Pancreatic Cancer  November 16th is observed as World Pancreatic Cancer…
December 18, 2023
Insights+ Key Biosimilars Events of November 2023
Insights+ Key Biosimilars Events of November 2023
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients   During November, Amgen received US FDA approval for Wezlana, biosimilar of ustekinumab &…
December 6, 2023
Know Your Investor: Alexandria Venture Investments
Know Your Investor: Alexandria Venture Investments
Shots: Know Your Investor’s November Edition revolves around Alexandria Venture Investments, which dedicatedly invests in the healthcare sector  Established in 1996, Alexandria Venture Investments is based in Pasadena, California, and is the corporate venture capital arm of Alexandria Real Estate Equities In 2022, Alexandria participated in 31 investment rounds, with Affini-T Therapeutics receiving the highest…
November 29, 2023
Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]